SystImmune, Inc. is a biopharmaceutical company dedicated to the development of innovative therapeutic solutions for cancer treatment, focusing on bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Their approach involves creating biologics that systematically target tumor microenvironments, directly attacking tumors while simultaneously activating the immune system to enhance its response against cancer cells. The company employs advanced technology platforms in protein engineering and antibody development, which include the incorporation of binding domains into proprietary antibody and ADC platforms, as well as the optimization of antibody properties such as stability and binding affinity.

In their antibody development process, SystImmune utilizes techniques such as B cell enrichment and sorting, as well as yeast display strategies, to identify monoclonal antibodies from rabbits and alpacas. This enables the selection of unique core assets through novel miniaturized immuno-assays. Additionally, SystImmune has established integrated and efficient production platforms based on CHO (Chinese Hamster Ovary) cells, which support their capabilities in downstream, upstream, formulation, and analytical processes necessary for manufacturing biotherapeutics. With a strong focus on R&D, SystImmune aims to advance its pipeline of therapeutics, targeting various solid tumors and hematological malignancies through their innovative drug development strategies.

United States

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

Systimmune

Company Details